Q-omics provides the consensus-scored CRLS1 profile across patient tissues and cancer cell-line models. CRLS1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CRLS1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CRLS1 RNA expression shows 18,799 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where CRLS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRLS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRLS1 survival associations across molecular data types. CRLS1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRLS1 RNA expression–survival associations across cancer types. High CRLS1 expression shows unfavorable associations in UVM, CHOL, KICH, KIRC and PAAD, but favorable associations in LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CRLS1 RNA expression.
This table summarizes CRLS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CRLS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRLS1 shows lower tumor expression in LUSC and LUAD and higher tumor expression in HNSC, BLCA, COAD and STAD. The HNSC box plot shows higher CRLS1 RNA expression in tumor versus normal tissue (log2 FC = +0.572, t-test p < 0.001).
This table shows molecular features associated with CRLS1 in patient tissues and cancer cell lines. In patient samples, CRLS1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CRLS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
